Cytek Biosciences Q3 revenue beats estimates, driven by recurring rev growth

Cytek Biosciences

05/11/2025 21:59

Overview

Cytek Q3 2025 revenue grows 2% yr/yr, beating analyst expectations

Net loss for Q3 2025 was $5.5 mln, compared to net income last year

Operating expenses increased 10% due to higher general and administrative costs

Outlook

Cytek Biosciences reaffirms 2025 revenue guidance of $196 mln to $205 mln

Company remains focused on expanding global installed base and recurring revenue streams

Cytek mindful of market conditions affecting profitability and cash generation

Result Drivers

INSTALLED BASE EXPANSION - Cytek added 161 units to its installed base, reaching 3,456 instruments

RECURRING REVENUE GROWTH - Service and reagent revenues grew 19% yr/yr

CUSTOMER SEGMENT GROWTH - Revenue from biotechnology, pharmaceutical, and CRO customers grew 14% yr/yr

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$52.29 mln
$51.50 mln (4 Analysts)
Q3 Net Income
-$5.48 mln
Q3 Adjusted EBITDA
$2.45 mln
Q3 Adjusted Gross Margin
53.00%
Q3 Pretax Profit
-$7.77 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Cytek Biosciences Inc is $4.25, about 8% above its November 4 closing price of $3.91

Press Release: ID:nGNX45dW07

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)